Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study

Nephrology Dialysis Transplantation

Volumn 26, Issue 11, 2011, Pages 3784-3793

  Lloberas, Nuria ^a   Torras, Juan ^a   Cruzado, Josep M ^a   Andreu, Franc ^a,b   Oppenheimer, Federico ^c   Sánchez Plumed, Jaime ^d   Gentil, Miguel Ángel ^e   Brunet, Mercé ^f   Ekberg, Henrik ^g   Grinyó, Josep M ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f Centre de Diagnostic Biomedic   (Spain)

^g Univ Hospital MAS   (Sweden)

Author keywords

Immunosuppressors; MRP2; mycophenolic acid; pharmacokinetics; single nucleotide polymorphism

Indexed keywords

7 O MYCOPHENOLIC ACID GLUCURONIDE; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; DRUG METABOLITE; MACROLIDE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; GENE; GENOTYPE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MRP2 GENE; MULTICENTER STUDY; PHARMACOGENOMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN;

AREA UNDER CURVE; CYCLOSPORINE; DNA; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; MYCOPHENOLIC ACID; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SIROLIMUS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TACROLIMUS;

EID: 80155171939     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr130     Document Type: Article

References (25)

1. Shipkova M, Armstrong VW, Weber L et al. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit 2002; 24: 390-399
2. Picard N, Ratanasavanh D, Premaud A et al. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 2005; 33: 139-146
3. Hesselink DA, van Hest RM, Mathot RA et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005; 5: 987-994
4. Westley IS, Brogan LR, Morris RG et al. Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: Effect of cyclosporine. Drug Metab Dispos 2006; 34: 261-266
5. de Jonge H, Naesens M, Kuypers DR. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: Possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit 2009; 31: 416-435
6. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: Characterization and relation to pharmacodynamics. Clin Chem 1995; 41: 1011-1017
7. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34: 429-455
8. Shaw LM, Korecka M, Venkataramanan R et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003; 3: 534-542
9. Levesque E, Delage R, Benoit-Biancamano MO et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther 2007; 81: 392-400
10. Naesens M, Kuypers DR, Streit F et al. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: Implications for drug exposure in renal allograft recipients. Clin Pharmacol Ther 2006; 80: 509-521
11. Satoh S, Tada H, Murakami M et al. Circadian pharmacokinetics of mycophenolic acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. Transplantation 2006; 82: 486-493
12. Dietrich CG, Geier A, Oude Elferink RP. ABC of oral bioavailability: Transporters as gatekeepers in the gut. Gut 2003; 52: 1788-1795
13. Masereeuw R, Notenboom S, Smeets PH et al. Impaired renal secretion of substrates for the multidrug resistance protein 2 in mutant transport-deficient (TR-) rats. J Am Soc Nephrol 2003; 14: 2741-2749
14. Suzuki H, Sugiyama Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): Its impact on drug disposition. Adv Drug Deliv Rev 2002; 54: 1311-1331
15. Ito S, Ieiri I, Tanabe M et al. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001; 11: 175-184
16. Naesens M, Kuypers DR, Verbeke K et al. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 2006; 82: 1074-1084
17. Lim SW, Li C, Sun BK et al. Long-term treatment with cyclosporine decreases aquaporins and urea transporters in the rat kidney. Am J Physiol Rentel Physiol 2004; 287: F139-F151
18. Elamiri A, Perwaiz S, Tuchweber B et al. Effect of mdr2 mutation with combined tandem disruption of canalicular glycoprotein transporters by cyclosporine A on bile formation in mice. Pharmacol Res 2003; 48: 467-472
19. Kobayashi M, Saitoh H, Tadano K et al. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 2004; 309: 1029-1035
20. Grinyo JM, Ekberg H, Mamelok RD et al. The pharmacokinetics of mycophenolatemofetil in renal transplant recipients receiving standarddose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: The Symphony pharmacokinetic substudy. Nephrol Dial Transplant 2009; 24: 2269-2276
21. Miura M, Satoh S, Inoue K et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 2007; 63: 1161-1169
22. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharma cokinet 2007; 46: 13-58
23. van Gelder T, Klupp J, Barten MJ et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23: 119-128
24. Naesens M, de Loor H, Vanrenterghem Y et al. The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. Transplantation 2007; 84: 362-373
25. Itoda M, Saito Y, Soyama A et al. Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: An association between single nucleotide polymorphisms in the 5'-untranslated region and exon 28. Drug Metab Dispos 2002; 30: 363-364